Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2004

View Archived Issues

First safety review completed for phase II study of HepeX-B

Target enrollment reached in ARISE study of AGI-1067 for atherosclerosis

MedImmune and Medarex to develop antibodies for autoimmune diseases

Cenomed licenses analogues for cognitive disorders from Medical College of Georgia

GSK profiles CNS pipeline

Enrollment temporarily suspended in phase III surgical study of Inactine system

Phase I data supports the use of IMOxine in cancer immunotherapy

GlaxoSmithKline to develop NS-2359 for depression

Trigen and Eurand to develop controlled-release TGN-167

Japanese launch of Valixa for CMV retinitis

New dosage forms of AG-013736

Coumarinolignoid composition for use as hepatoprotective agent described in patent

Agent for fungal infections and cancer isolated from lichen

Scientists at Aventis claim new azetidinone and its use as a treatment for hyperlipidemia

Novel cathepsin K inhibitors in early development at Sankyo

New insulin secretagogues claimed in Bayer patent

Indian researchers isolate antibacterial agent from Cymbopogon flexuosus

Novel agent by Microbia shows antinociceptive effects in animal models of visceral pain

Neuronal Shp2 tyrosine phosphatase targeted for the treatment of obesity

Chondroprotective effects of glucosamine analogue against osteoarthritis

Bifunctional small molecules inhibit Abeta aggregation

Ferumoxtran-10 improves MRI detection of metastatic nodes in bladder cancer

Antihypertensive effects found for rosiglitazone in diabetics with hypertension

Merimepodib increases virological response to interferon plus ribavirin therapy in hepatitis C

HepeX-B reduces viral load of patients with chronic HBV infection

Two-year data on the effects of statins on glycemic control

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...